The Core Essentials of Immuno-Oncology Now and Into the Future: Pathophysiology, Mechanisms, Immunotherapy, and irAEs - Activity 3: Mechanisms Underlying irAEs
The Core Essentials of Immuno-Oncology Now and Into the Future: Pathophysiology, Mechanisms,
Immunotherapy, and irAEs
Activity 3: Mechanisms Underlying irAEs
Release Date: June 30, 2020
Last Reviewed: June 22, 2020
Expiration Date: June 30, 2021
Time to Complete Activity: 0.5 hour
*This activity expired for credit on June 30, 2021 and is no longer available for credit
Elizabeth I. Buchbinder, MD
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Comprehensive Cancer Center
New Haven, CT
Michael J. Overman, MD
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
This activity is provided by Paradigm Medical Communications, LLC.
This activity has been designed to address the educational needs of oncology, hematology, and pathology clinicians, including physicians, nurse practitioners, PAs, pharmacists, and other healthcare professionals working as part of the multidisciplinary oncology care team.
Upon proper completion of this activity, participants should be better able to:
- Describe fundamental elements of cancer immunology, including interactions between the innate and adaptive immune mechanisms within the tumor microenvironment that result in tumor evasion of the immune system
- Outline how established and emerging agents act on immuno-oncology pathways
- Explain the underlying mechanisms of immune-related adverse events (irAEs) associated with immuno-oncology agents, which result in a different safety profile than that of conventional chemotherapy
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 0.5 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
Program expires 6/30/2021
Pharmacist Accreditation and Designation Statement
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 0.5 contact hours (0.05 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN # 0761-9999-20-097-H01-P
This is a knowledge-based activity.
This activity is jointly provided by Educational Review Systems, Inc and Paradigm Medical Communications, LLC.
PA Continuing Education
PAs may claim a maximum of 0.5 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
This activity is supported by educational grants from Bristol-Myers Squibb and Merck & Co., Inc.
Instructions for Participation
To receive credit, you should:
- Follow instructions to register or log in with your professional information and complete the preactivity assessment
- View the online activity in its entirety
- Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest
Please note: To claim CPE credit, please make sure you include your date of birth and NABP number. All credit information will be uploaded into CPE Monitor within 30 days.
For questions regarding CE credit, contact the Paradigm CME Department at (845) 398-5949.
There is no fee required for participation in this activity.
This certified CME activity is designed using HTML5 media controls.
For desktops (Windows/Mac)
Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher
For Tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher
Technical Support: If you have any technical problems or playback issues email us at firstname.lastname@example.org.
In accordance with ACCME, ACPE, and ANCC requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.
Elizabeth I. Buchbinder, MD
No financial relationships to disclose
Roy S. Herbst, MD, PhD
Scientific Advisory Boards: Infinity Pharmaceuticals, Inc; Neon Therapeutics; NextCure, Inc
Consulting Fees: AbbVie, Inc; ARMO Biosciences, Inc; AstraZeneca; Biodesix; Bolt Biotherapeutics, Inc; Bristol-Myers Squibb; Eli Lilly and Company; EMD Serono, Inc; Genentech, Inc/Roche; Genmab; Halozyme, Inc; Heat Biologics, Inc; I-Mab Biopharma; Immunocore; Loxo Oncology; Merck & Co., Inc; Midas Health Analytics; Mirati Therapeutics, Inc; Nektar; NextCure, Inc; Novartis Pharmaceuticals Corporation; Pfizer Inc; sanofi-aventis U.S. LLC; Seattle Genetics, Inc; Shire Plc; Spectrum Pharmaceuticals, Inc; Symphogen; Takeda; Tesaro, Inc; Tocagen
Grant/Research Support: AstraZeneca; Eli Lilly and Company; Merck & Co., Inc
Other (Board Member): Shanghai Junshi Biosciences Co., Ltd.
Michael J. Overman, MD
Consulting Fees: Array BioPharma; AstraZeneca; Bristol-Myers Squibb; CatalYm; Gritstone Oncology; Novartis Pharmaceuticals Corporation; Promega Corporation; Roche; Takeda
Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.
Educational Review Systems, Inc staff members have no financial relationships to disclose.
Independent peer reviewer has no financial relationships to disclose.
Resolution of Conflict of Interest
Paradigm Medical Communications, LLC and Educational Review Systems, Inc have implemented a system to resolve conflicts of interest for each CE activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CE content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ANCC Guidelines, ACPE Guidelines, and ACCME’s Standards for Commercial Support of Continuing Medical Education.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
This CE activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC or Educational Review Systems, Inc. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As accredited providers, Paradigm Medical Communications, LLC and Educational Review Systems, Inc’s activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC or Educational Review Systems, Inc.
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CE activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC or Educational Review Systems, Inc. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC or Educational Review Systems, Inc. Paradigm Medical Communications, LLC and Educational Review Systems, Inc accept no liability for the content referenced in this activity.
Paradigm Medical Communications, LLC and Educational Review Systems, Inc or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CE activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC and Educational Review Systems, Inc to continuously improve the learning experience.
Paradigm Medical Communications, LLC and Educational Review Systems, Inc do not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC and Educational Review Systems, Inc will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC and Educational Review Systems, Inc staff members review individual test results to the extent necessary to record and track participants’ credits.
If you have any questions or comments, please email us at email@example.com.
© 2020 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.